Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Fingolimod placebo, FINGOLIMOD, Ublituximab Placebo, ublituximab
TG THERAPEUTICS, INC.
Relapsing Multiple Sclerosis
1 trial -
Flucelvax Tetra - suspension for injection in pre-filled syringe Influenza vaccine (surface antigen, inactivated, prepared in cell cultures), PNEUMOVAX solution injectable en flacon Vaccin pneumococcique polyosidique, Pneumovax 23 oldatos injekció előretöltött fecskendőben Pneumococcus-poliszacharid vakcina, BOOSTRIX, suspension injectable en seringue préremplie Vaccin diphtérique, tétanique et coquelucheux (acellulaire multicomposé), (adsorbé, à teneur réduite en antigènes), Pneumovax 23 oldatos injekció e
Novartis Pharmaceuticals
Relapsing multiple sclerosis (RMS)
1 trial -
GEMCITABINE , CARBOPLATIN , MIRVETUXIMAB SORAVTANSINE, TOPOTECAN , LY4170156, BEVACIZUMAB , PACLITAXEL , DOXORUBICIN
Eli Lilly Co.
Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms, Neoplasm Metastasis
1 trial -
GLASDEGIB , DAUNORUBICIN , AZACITIDINE , AMSACRINE , CYTARABINE , DECITABINE , FLUDARABINE , ETOPOSIDE , GILTERITINIB, IDARUBICIN , VENETOCLAX , MITOXANTRONE , IVOSIDENIB , CYTARABINE , CLADRIBINE , GEMTUZUMAB OZOGAMICIN
Istituto Gentili S.r.l.
Acute myeloid leukemia
1 trial -
GWP42003-P
Jazz Pharmaceuticals Ireland Limited
Infantile Spasms
2 trials -
General anesthesia and opioids
Elan Pharma International
Breast Neoplasms
1 trial -
HYDROXYCHLOROQUINE, METHOTREXATE, Remsima 120 mg solution for injection in pre-filled pen, METHOTREXATE, IBUPROFEN, Placebo (To evaluate the efficacy and safety of CT-P13, and mainatain blindness during the study, Placebo will be administered.), PARACETAMOL, FOLIC ACID, HYDROCORTISONE
Celltrion Healthcare Australia Pty Ltd
Rheumatoid arthritis
1 trial -
Herceptin
Hoffmann-La Roche
Breast Neoplasms
1 trial -
IV Tulisokibart
Merck KGaA, Darmstadt, Germany
Crohn's Disease
1 trial -
IV Tulisokibart
Merck KGaA, Darmstadt, Germany
Ulcerative Colitis
1 trial -
Instant MSC Product accompanying Autologous Chondron Transplantation (IMPACT)
Disc Medicine
Symptomatic articular cartilage lesion of the knee (femoral condyles or trochlea)
1 trial -
Intermittent hepatic inflow occlusion (IHIO)
Samsung Bioepis NL B.V.
End Stage Liver Disease
1 trial -
Intrarosa 6.5 mg pessary
Istituto Gentili S.r.l.
Postmenopausal women with previous breast cancer or currently under anti-oesterogenic therapy (aromatase inhibitor +/- LHRH analogue) presenting vulvar, vaginal or urinary bothersome symptoms (genitourinary syndrome).
1 trial -
Jinarc 30 mg tablets, Tolvaptan, Jinarc 15 mg tablets, Samsca 7.5 mg tablets
Otsuka Beijing Research Institute
Autosomal Recessive Polycystic Kidney Disease
1 trial -
KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Samsung Bioepis NL B.V.
Non-small Cell Lung Cancer
1 trial -
KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion
Ningbo Cancer Hospital
Uveal Melanoma
1 trial -
Kesimpta 20 mg solution for injection in pre-filled pen, Kesimpta 20 mg solution for injection in pre-filled pen
Novartis Pharmaceuticals
relapsing multiple sclerosis (RMS)
1 trial -
LHRHa
Janssen Cilag International NV
Prostatic Neoplasms
1 trial -
LPA1 antagonist, LPA1 antagonist, Placebo for BMS-986278
Bristol-Myers Squibb Australia Pty Ltd
Idiopathic pulmonary fibrosis
1 trial -
LPA1 antagonist, Placebo for BMS-986278, LPA1 antagonist
Bristol-Myers Squibb Australia Pty Ltd
Progressive Pulmonary Fibrosis
1 trial -
Lapatinib
GlaxoSmithKline
Neoplasms, Head and Neck
1 trial -
Lapatinib
Novartis Pharmaceuticals
Neoplasms, Breast
2 trials -
Lapatinib
Novartis Pharmaceuticals
Breast Neoplasms
1 trial -
Lenvatinib
Merck KGaA, Darmstadt, Germany
Carcinoma, Hepatocellular
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources